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ABSTRACT 
 
Background:  HIV/AIDS is one of the most destructive and lethal health crises of 
today’s world. The stigma and resulting discrimination of HIV/AIDS is almost as 
deadly as the virus itself. Because a vaccine or cure does not exist, HIV/AIDS will 
continue to spread and therefore, prevention remains the key to curbing this 
epidemic.  One method of combating this disease is through the administration of 
preexposure chemoprophylactic agents prior to the exposure of the infectious 
agent.  For this systematic review, the evidence from two studies were evaluated 
using the GRADE tool. 
 
Method:  An exhaustive search of available medical literature was conducted 
using Medline, Web of Science, Cochrane Systematic Reviews, CINHAL, and 
EBM Multifile Review. 
 
Results:  Two randomized controlled trials were reviewed.  Both studies showed 
a reduction in HIV/AIDS acquisition with the use of anti-retroviral preexposure 
prophylaxis. 
 
Conclusion:  The administration of anti-retroviral preexposure chemoprophylaxis 
decreases the transmission rate of infection. The GRADE for the evidence was 
high. 
 
Keywords: HIV, Anti-Retroviral Agents, Prevention, and Tenofovir. 
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INTRODUCTION 
Background 
The Human Immunodeficiency Virus/Acquired Immunodeficiency 
Syndrome (HIV/AIDS) is one of the most destructive and lethal health crises in 
today’s world.  This major health emergency has continued to ravage families 
and communities across the globe for nearly thirty years despite the continued 
efforts to develop an effective vaccine.  The armamentarium for preventing the 
transmission of HIV/AIDS and decreasing the impact of this deadly disease are 
continuing to slowly propagate.  Although its exact origins are uncertain, it is 
largely believed HIV/AIDS came about through the interaction of humans with 
other species, likely as a result from apes being hunted, butchered, or eaten 
(New Yorker, 2010).  According to AVERT (2010), an international HIV/AIDS 
charity, an estimated 33.3 million people worldwide were living with HIV/AIDS in 
2009, with women accounting for just over half of all adult cases.  AVERT (2010) 
also published that 1.8 million HIV/AIDS deaths were reported in the same year.  
Every day, more than 7,000 people are newly infected around the globe with 
HIV/AIDS (AVERT, 2010).  This pandemic continues to spread globally in spite of 
the many prevention efforts.   
Discrimination, social unrest, maltreatment and abuse are a few problems 
that undermine the human rights of those who are HIV/AIDS positive (World 
Health Organization [WHO], 2006).  The stigma and resulting discrimination of 
HIV/AIDS along side misogyny which leads to homosexual and heterosexual 
behaviors continues to impact the spread of the virus.  HIV/AIDS continues to be 
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a barrier to public action while also remaining a social issue which people are 
reluctant to address.  In continents such as Africa, that have been heavily 
impacted by the HIV/AIDS epidemic, the losses of individuals and productive 
citizens have not only affected family units but have also affected workplaces, 
schools, health systems and governments (Ashford, 2006).  According to Ashford 
(2006), this epidemic has touched every single facet of the living.  Because a 
vaccine or cure does not exist, HIV/AIDS will continue to spread and therefore, 
prevention remains the key to curbing this pandemic.   
The only known way for HIV/AIDS transmission to take place is through 
direct contact with the blood or bodily fluids (semen, vaginal fluid, preseminal 
fluid and breast milk) of someone who is infected with the virus (AVERT, 2011).  
Like other viruses, HIV/AIDS can only sustain life in living organisms.  The most 
common ways in which HIV/AIDS is propagating throughout the world is through 
contact between sexual secretions of one person with the genital, rectal or oral 
mucosa membranes of another person, sharing injection paraphernalia to 
transfuse blood, inject drugs or other substances, and by transmission from 
infected mothers to their newborns during pregnancy, labor, or breastfeeding 
(AVERT, 2011).  Although the risk of HIV/AIDS contagion is very low through 
casual exposure, it is still theoretically possible.  Antibody testing remains the 
best method for diagnosis.   
Prevention of HIV/AIDS is the key to eliminating this deadly virus.  Current 
practices that have been shown to decrease the transmission of HIV/AIDS are 
abstinence, delaying the age at which young people first engage in sexual 
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intercourse, monogamy, education, condom promotion and use, improved 
access to condoms, male circumcision, substance addiction therapy, treatment of 
sexually transmitted infections and HIV/AIDS testing and counseling (WHO, 
2006).  A recent study conducted in Africa performed by Peterson et al. (2007) 
demonstrated with proper education people will change their sexual behavior.  In 
this study, self reported condom use increased from 52 percent at screening to 
approximately 92 percent during the follow up period (Peterson el al., 2007).  The 
conjecture in this increased condom use reflects the services that were provided 
such as HIV/AIDS testing and counseling services and the dispensing of 
condoms (Peterson et al., 2007).  Youth are at the core of the global HIV/AIDS 
epidemic, both in terms of new infections and in opportunities for halting the 
transmission (WHO, 2006).  Providing youth with HIV/AIDS education is vital and 
can only help to contain the current population infected, and protect against 
future spread.  The most recent dramatic success in prevention has been the 
reduction of mother to child transmission through the use of anti-retroviral (ARV) 
chemotherapeutics.  This development has led many recent trials and 
investigations to take a closer look at preexposure chemoprophylaxis (PrEP) 
therapy with the use of ARVs by HIV/AIDS negative individuals to reduce their 
overall risk of acquiring the virus.  The use of ARV therapy for prevention of 
HIV/AIDS can lead to suppression of viral replication in the bloodstream and in 
genital tract secretions, which then would decrease transmission of this deadly 
disease (El-Sadr, 2010).   
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One such ARV is tenofovir, which is an anedenosine nucleotide analogue 
belonging to a class of antiviral medications that is called reverse transcriptase 
inhibitors (National Center for Biotechnology Information [NCBI], 2010b).  
Tenofovir has potent activity against retroviruses and works by slowing the 
spread of HIV/AIDS in the body (NCBI, 2010b).  It was initially developed and 
tested as a prophylactic ARV drug on monkeys and was subsequently formulated 
for oral use to treat HIV/AIDS in humans (NCBI, 2010b).  When used in 
conjunction with tenofovir and other drugs, emtricitabine is another ARV used to 
treat HIV/AIDS.  Emtricitabine also works by slowing the spread of HIV/AIDS in 
the body by inhibiting reverse transcriptase, the enzyme that copies HIV/AIDS 
RNA into new viral DNA (NCBI, 2010a).  Emtricitabine can help to lower the 
amount of HIV/AIDS, also known as the "viral load" in a patient's body by 
indirectly increasing the number of immune system cells overall which decreases 
the likelihood of acquiring the infection (NCBI, 2010a).  Scientific evidence 
increasingly supports the view that ARV therapy is effective in reducing the risk 
of HIV/AIDS transmission by sustained suppression of the virus.  In the same 
fashion ARV therapy can also impact couples with a discordant serostatus by 
lowering transmission (WHO, 2009).  Prevention of mother to child transmission 
through the use of ARVs is proof of this concept.  These pharmacological agents 
control the infection but do not cure it (NCBI, 2010).  There are a number of 
biomedical technologies under development that show promise for preventing the 
spread of HIV/AIDS, unfortunately it may take years for these interventions to 
come to fruition. 
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Purpose of the Study 
There is no cure for HIV/AIDS.  Because of this, any strategies that will 
prevent the spread of the disease or the use of any medications that will 
decrease transmission of the disease are an important avenue to investigate. 
Several studies have suggested that PrEP is efficacious in preventing HIV/AIDS, 
however, insufficient research has been performed to date.  The objective of this 
paper is to perform a systematic review of the literature on the use of ARV PrEP 
in high risk adults to determine if it will prevent or reduce the transmission of 
HIV/AIDS.  In order to provide an objective evaluation, the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) tool 
developed by the GRADE Working Group has been used (Guyatt et al., 2008). 
METHODS 
An extensive literature search was performed using Medline, Web of 
Science, Cochrane Systematic Reviews, CINHAL, and Evidence-Based Medicine 
Reviews Multifile.  These databases were accessed through the Pacific 
University Library system.  The keywords searched included “HIV”, “Anti-
Retroviral Agents”, “Prevention”, and “Tenofovir” individually and in combination.  
The search was limited to human subjects, the English language and full text 
articles.  The initial results included 16 articles.  Articles published before 2000 
were excluded.  Only randomized, controlled trials were located which resulted in 
two studies that were directly related to the topic being reviewed.  One study was 
conducted in South Africa and the other study was conducted multi-nationally. 
RESULTS 
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The first study reviewed was performed by Grant et al., (2010) and 
appeared in the New England Journal of Medicine.  The purpose of this study 
was to evaluate the safety and efficacy of oral emtricitabine (FTC) and tenofovir 
disoproxil fumarate (TDF) combination therapy (FTC-TDF) in a single tablet as 
compared to placebo for the prevention of HIV/AIDS.  This study enrolled 2,499 
participants at eleven sites in six countries: Peru, Ecuador, South Africa, Brazil, 
Thailand, and the United States.  Inclusion criteria were male sex at birth, an age 
of eighteen years or older, HIV seronegative status and evidence of high risk for 
acquisition of HIV/AIDS infection (Grant et al., 2010).  Each four-week visit 
included medical histories, drug dispensing, pill counts, adherence counseling, 
and rapid testing for HIV antibodies.  The interviewer assessed high risk behavior 
every twelve weeks.  Physical examination and evaluation for sexually 
transmitted infections was performed every 24 weeks.  HIV/AIDS rapid testing 
was performed at 39,613 visits.  New or emergent HIV/AIDS sero-conversion 
was observed in 100 patients.  Among those 100 patients, 36 of them were in the 
FDC-TDF group and 64 of them were in the placebo group.  This represented a 
44 percent reduction in the new HIV/AIDS cases.  The rate of compliance was 50 
percent and was consistent across both the experimental and the placebo group.  
Furthermore, after discontinuation of the study drug, seroconversion rates were 
similar among the study groups.  Drug levels were drawn, and of those with a 
detectable level, the odds of HIV/AIDS infection were lower by a factor of 12.9, 
corresponding to a relative reduction rate of HIV/AIDS of 92 percent.  No FDC or 
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TDF resistance was detected during the study.  Detectable blood levels strongly 
correlated with the prophylactic effect. 
The side effects from FTC-TDF were mild and sparse.  The most common 
side effect reported were nausea and unintentional weight loss of greater than 
five percent.  Both were reported more frequently in the FTC-TDF group than the 
placebo group.  No FTC or TDF resistance occurred in any of the participants 
who became infected with HIV/AIDS during the trial.  A mild increase in 
creatinine levels suggestive of renal impairment were observed in the FTC-TDF 
group but were self limiting and were not confirmed on specific repeat testing 
(Grant et al., 2010).  Self reported HIV/AIDS sexual risk behavior decreased in 
both arms of the study.  The authors concluded that PrEP of FTC-TDF in high 
risk adult populations is effective in slowing the spread of HIV/AIDS (Grant et al., 
2010). 
The second study reviewed was conducted by The AIDS Program of 
Research in South Africa (CAPRISA) by Karim et al., (2010).  The purpose of this 
study was to assess the effectiveness and safety of tenofovir gel for the 
prevention of HIV/AIDS infections in women vaginally.  The authors enrolled 889 
participants in the analysis.  HIV/AIDS negative women from eighteen to forty 
years old who were sexually active (defined as having sex at least twice in the 30 
days before screening), not pregnant, and using a nonbarrier form of 
contraceptive were eligible for enrollment (Karim et al., 2010).  Women were 
requested to insert one dose of tenofovir gel into their vagina within twelve hours 
before sex and a second dose of gel as soon as possible but within twelve hours 
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after sex.  No more than two doses of gel in a 24-hour period were to be used 
(Karim et al., 2010).  Each participant had monthly HIV/AIDS and urine 
pregnancy testing performed before gel was dispensed.   Compliance was 
measured by self report.  Drug safety was assessed at every study visit.  
Participants underwent quarterly pelvic examinations, and if needed, colposcopy 
(Karim et al., 2010).  HIV/AIDS incidence rate in the tenofovir gel arm when 
compared with the placebo gel arm, was 50 percent lower after twelve months of 
follow up and 40 percent lower after 24 months of follow up (Karim et al., 2010).  
In terms of assessing the effectiveness of the gel in preventing HIV/AIDS 
infection, 98 HIV/AIDS infections occurred throughout the study, 38 in the 
tenofovir gel arm and 60 in the placebo arm yielding an incidence rate ratio of 
0.61.  It reduced HIV/AIDS acquisition by an estimated 39 percent overall, and by 
54 percent in women with high level of gel adherence (Karim et al., 2010).  The 
hazard ratio was 0.63 after adjusting for baseline co-variants (age, site, anal sex 
history, contraceptive method, HSV-2 antibody status, and condom use).  The 
adherence estimates based on applicators returned indicated 72.2 percent of sex 
acts were covered by two doses of gel (Karim et al., 2010).  HIV/AIDS incidence 
was directly correlated to the number of doses utilized.  The participants with a 
high level of adherence were 54 percent less likely to become infected with the 
virus whereas the less adherent participants were 38 percent less likely to 
become infected (Karim et al., 2010). The number of sex acts were indirectly 
proportional to the quantity of gel utilized.  Adherence was found to be higher in 
women who did not acquire HIV/AIDS.  The gel provided a 51 percent protective 
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effect against herpes simplex virus type 2 infection (Karim et al., 2010).  There 
were no tenofovir resistance or resistant mutations detected in the tenofovir or 
the placebo arm.  More diarrhea and gastrointestinal infections were reported 
among the participants using the tenofovir gel, but otherwise adverse events and 
other safety markers were very similar between the two study arms.  No safety 
concerns were identified in the 22 women exposed to tenofovir gel in early 
pregnancy.  No congenital abnormalities were seen in the babies born during the 
study.  TDF has been shown to cause decreases in renal function.   Whether this 
serves as a confounder of renal impairment, this will remain unknown because 
women with renal impairment were excluded from the CAPRISA study.  Liver 
side effects or increases in heptic flares were not seen during the study, possibly 
because of the low systemic absorption of the tenofovir gel epicutaneously.  The 
authors concluded that when tenofovir gel was used coitally, it appeared safe 
and effective in preventing HIV/AIDS infection (Karim et al., 2010).   
 
 
DISCUSSION 
General 
The results of the CAPRISA trial, released in July 2010, showed that one 
percent tenofovir gel reduced the risk of HIV/AIDS infection in women by 39 
percent compared with placebo, and increased incrementally as the women were 
more consistent with gel use (Karim et al., 2010).  In some cases this was as 
high as 54 percent.  This was the first clinical trial in almost twenty years to show 
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that a vaginal microbicide could provide a safe and effective way to prevent 
sexual transmission of HIV/AIDS.  Interestingly the gel also provided a protective 
effect against herpes simplex virus type 2 infection (Karim et al., 2010). 
In the Preexposure Chemoprophylaxis for HIV in Men Who Have Sex With 
Men (iPrEx) study, the arm that received ARV PrEP experienced an average of 
44 percent fewer HIV/AIDS infections than the arm that received placebo (Grant 
et al., 2010).  The authors reported 36 infections in the patients receiving FTC-
TDF and there were 64 infections in participants receiving placebo (Grant et al., 
2010).   
Limitations 
There were a number of study limitations observed in both studies 
reviewed.  The study by Grant et al. (2010) had a recall bias because the 
subjects were interviewed every 12 weeks to review their sexual risk behavior.  
Reported high risk behavior substantially decreased after enrollment and 
remained lower than at baseline during the trial (Grant et al., 2010).  A similar 
study in Western Africa showed a safer behavior in a trial of PrEP with TDF 
(Peterson et al., 2007).  It is hypothesized that this may reflect the services that 
were provided such as HIV/AIDS testing and counseling services and the 
dispensing of condoms (Peterson et al., 2007).  Furthermore, taking a pill may 
serve as a daily reminder of the risks one is undertaking, possibly leading to 
changes in sexual behavior overall reducing one’s risk of acquiring HIV/AIDS.  
Gel does not serve as a behavioral reminder because typically the decision has 
already been made to have sex when the gel is being used.  Gel use is not 
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blinded to the study participant’s partner, therefore, it may alter the practices of 
the sexual encounter.  The cultural mores in different locations where studies 
were conducted would play a large role in determining the final results if the sites 
in Africa for example, might demonstrate the lack of autonomy of African women 
in making sexual decisions for themselves as compared to those in the United 
States.  If individuals taking ARV PrEP feel protected against infection and 
consequently increase their risky behavior, risk compensation will likely occur 
(Supervie, 2010).  Risk compensation is when individual people may tend to 
adjust their behavior in response to perceived changes in risk.  This could 
potentially escalate the transmitted resistance.  For example, the male may be 
willing to take more risks because of the mindset that one’s partner is “protected” 
when the gel is being used.  It also may alter the type of sex that is being had 
and may change the sensation or frequency of encounters due to changing the 
experience of sex either in a positive or negative manner, i.e. better sensation 
through decreased friction.  The sexual act may become more pleasurable with 
the use of gel for the woman if she suffers from vaginal dryness, therefore, she 
might become more willing to participate in riskier sexual encounters.  The pill 
consumption is unknown to the sexual partner and therefore, not subject to any 
behavior modifications based on knowledge of its use.  Another limitation of this 
study is the heterogeneity of the sexual practices being performed i.e. 
heterosexual women and bisexual men (Grant et al., 2010).  It is not known 
whether the gel protects against the rectal transmission of HIV/AIDS thus 
providing study participants with gel may actually serve to increase their 
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HIV/AIDS transmission rate, i.e. risk compensation, through the facilitation of 
high risk behavior.  
Limitations were also present in the CAPRISA trial (Karim et al., 2010).  
This study also has a recall bias because it asks participants to self-report sex 
acts in the last 30 days and the adherence to the use of gel.  Both are likely to be 
skewed by recall bias.  Participants undoubtedly under report their sexual 
acts/encounters and over reported their use of the gel.  This was clear from the 
drug levels not matching the self reported numbers.  One of the differences in 
this study is that they only enrolled women due to the common perception that 
men and women do not work in conjunction to address these issues in this 
location.  The mechanics of the sexual activity naturally result in one of the 
sexual partners being subject to greater harm.  For instance, pregnancy is a 
confounder which may theoretically increase the acquisition of HIV/AIDS since 
the body is in an immunocompromised state.  High risk sex indirectly leads to 
increased risk of acquisition of HIV/AIDS.  The CAPRISA study did not explore 
whether the use of tenofovir in combination with other ARVs such as 
emtricitabine would offer more protection against HIV/AIDS. 
Strengths 
One strength of the CAPRISA trial is the blinding aspect of being able to 
use gels so it could look like everyone is taking the same substance (Karim et al., 
2010).  The authors were able to blind the participants to the use of the tenofovir 
versus the placebo gel.  This eliminated some of the potential bias and risk 
compensation behaviors that were seen in the study by Grant et al. (2010).  
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Another strength of this study is the analysis models used that account for risk 
compensation. 
Safety 
In the CAPRISA trial, overall there was a very little increase in the rate of 
side effects with the use of tenofovir gel (Karim et al., 2010).  More diarrhea and 
gastrointestinal infections were reported among the participants using the 
tenofovir gel, but otherwise adverse events and other safety markers were very 
similar between the two study arms.  No safety concerns were identified in the 22 
women exposed to tenofovir gel in early pregnancy.  No congenital abnormalities 
were seen in the babies born during the study.  TDF has been shown to cause 
decreases in renal function.   Whether this serves as a confounder of renal 
impairment, this will remain unknown because women with renal impairment 
were excluded from the CAPRISA study.  In both the tenofovir and in the placebo 
arm, no evidence of tenofovir resistance was found.  Liver side effects or 
increases in heptic flares were not seen during the study, possibly because of the 
low systemic absorption of the tenofovir gel epicutaneously.  In conclusion, no 
substantial safety concerns were found with the use of vaginal tenofovir gel and it 
was well tolerated across the board. 
In the iPrEx trial, side effects from FTC-TDF were mild and sparse (Grant 
et al., 2010).  The most common side effect reported were nausea and 
unintentional weight loss of greater than five percent.  Both were reported more 
frequently in the FTC-TDF group than the placebo group.  No FTC or TDF 
resistance occurred in any of the participants who became infected with 
  
18 
18 
HIV/AIDS during the trial.  A mild increase in creatinine levels suggestive of renal 
impairment were observed in the FTC-TDF group but were self limiting and were 
not confirmed on specific repeat testing (Grant et al., 2010).  Self reported 
HIV/AIDS sexual risk behavior decreased in both arms of the study.  To 
conclude, daily use of PrEP of FTC-TDF appears safe and is well tolerated. 
GRADE 
Clinical guidelines are only as good as the evidence and judgments they 
are based upon.  GRADE is a guideline and evaluation tool used to rate the 
quality of a body of evidence (Guyatt et al., 2008).  GRADE helps guide clinicians 
in making informed cognizant healthcare management decisions that aim at 
causing no harm to the patient.  GRADE was developed by a group of individuals 
worldwide.  It clearly separates between quality of evidence and strength of 
recommendation (Guyatt et al., 2008).  Determining the quality of evidence is 
crucial when making medical decisions on the behalf of one’s patients.  GRADE 
does this by categorizing the quality of evidence from high to very low making it 
obvious for clinicians to understand the merit in the evidence.  The 
recommendation is rated as either strong or weak to aid the clinician in making 
the best possible health management decision (Guyatt et al., 2008).  The two 
studies analyzed were rated as high quality evidence originally and remained 
high because they had few study limitations, the results were consistent, the 
evidence was direct with precision, and they lacked reporting biases (Appendix: 
GRADE table).  The recommendation for these studies was strong because the 
effects of the pharmacological interventions were desirable with low side effects.    
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Conclusion 
The HIV/AIDS pandemic is indeed global, although its primary distribition 
is in sub-Saharan Africa (UNAIDS, 2010).  Controlling the spread of HIV/AIDS 
has been a vexing and labyrinthine epidemiological health crisis that has not in 
three decades been conquered.  According to Wohl (2010), keeping one person's 
virus laden fluids away from the vulnerable cells of another is something most 
with a well developed frontal cortex can figure out how to do…yet we as a globe 
have yet to prevail a cure.  The unchanged magnitude of new infections each 
year clearly demarcates the need for pioneering superior prevention strategies 
and care programs.  Comprehensive and targeted HIV/AIDS prevention 
strategies is key to reversing this pandemic which includes exploring the test and 
treat approach (El-Sadr, 2010).  Embarking on such an effort as eradicating 
HIV/AIDS will require a cascade of events beyond formulating a pharmacological 
agent.  Exercising the use of the current ARV drugs used to treat HIV/AIDS may 
soon become the new chemical condom.  Currently, it has yet to be completely 
proven to be the magic grenade to bringing the HIV/AIDS pandemic to 
adjournment, but the future is promising.  Based on the findings in this systematic 
review, clinicians should consider recommending ARV PrEP combination therapy 
to high risk patients to prevent the acquisition of HIV/AIDS.  In both studies, the 
cumulative probability of HIV/AIDS acquisition in patients who received ARV 
PrEP was substantially lower than the placebo group.  This advance in HIV/AIDS 
prevention research may seem like a small preventative effect statistically, but it 
is rather significant considering we have had nothing that has shown a promising 
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decline besides abstinence and condom use.  Much more work lies ahead thus 
the many studies in the pipeline, but at least a good starting point has been 
established.   
Direction of future research might encompass anal sex transmission rates 
and HIV/AIDS when using a microbicide.  The use of FTC-TDF or other ARVs in 
women and post exposure chemoprophylaxis therapy are also other avenues to 
be further explored. 
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